Please use this identifier to cite or link to this item: https://libjncir.jncasr.ac.in/xmlui/handle/10572/574
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReddy, P Sreekanth-
dc.contributor.authorUmesh, Srikantha-
dc.contributor.authorThota, Balaram-
dc.contributor.authorTandon, Ashwani-
dc.contributor.authorPandey, Paritosh-
dc.contributor.authorHegde, A S-
dc.contributor.authorBalasubramaniam, Anandh-
dc.contributor.authorChandramouli, B A-
dc.contributor.authorSantosh, Vani-
dc.contributor.authorRao, M R S-
dc.contributor.authorKondaiah, Paturu-
dc.contributor.authorSomasundaram, Kumaravel-
dc.date.accessioned2012-03-07T06:02:12Z-
dc.date.available2012-03-07T06:02:12Z-
dc.date.issued2008-05-
dc.identifier1538-4047en_US
dc.identifier.citationCancer Biology & Therapy 7(5), 663-668 (2008)en_US
dc.identifier.urihttps://libjncir.jncasr.ac.in/xmlui/10572/574-
dc.descriptionRestricted Accessen_US
dc.description.abstractMalignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV). GBM is the most malignant with a median survival of 10-12 months in patients. Using cDNA microarray based expression profiling of different grades of astrocytomas, we identified several fold increased levels of PBEF1 transcripts in GBM samples. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes Nicotinamide phosphoribosyltransferase (NAmPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. Further validation using real time RT-qPCR on an independent set of tumor samples (n = 91) and normal brain samples (n = 9), GBM specific higher expression of PBEF1 was confirmed. Immunohistochemical staining for PBEF1 on a subset of the above samples largely reinforced our finding. We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade. PBEF1 serum levels were substantially elevated in many of the AA and GBM patients. Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM. Immunohistochemical analysis of an independent set of 51 retrospective GBM cases with known survival data revealed that PBEF1 expression in the tumor tissue along with its co-expression with p53 was associated with poor survival. Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs.en_US
dc.description.urihttp://dx.doi.org/10.4161/cbt.7.5.5663en_US
dc.language.isoenen_US
dc.publisherLandes Bioscienceen_US
dc.rights© 2008 Landes Bioscienceen_US
dc.subjectgliomaen_US
dc.subjectastrocytomaen_US
dc.subjectglioblastoma multiformeen_US
dc.subjectmicroarrayen_US
dc.subjectPBEF1en_US
dc.subjectserum markeren_US
dc.subjectsurvival analysisen_US
dc.subjectnampten_US
dc.subjectvisfatinen_US
dc.subjectprognosisen_US
dc.subjectColony-Enhancing Factoren_US
dc.subjectNicotinamide Phosphoribosyltransferaseen_US
dc.subjectGlioblastomaen_US
dc.subjectSurvivalen_US
dc.subjectTherapyen_US
dc.subjectCanceren_US
dc.subjectExpressionen_US
dc.subjectApoptosisen_US
dc.subjectProfileen_US
dc.subjectGenesen_US
dc.titlePBEF1/NAmPRTase/Visfatin - A potential malignant astrocytoma/glioblastoma serum marker with prognostic valueen_US
dc.typeArticleen_US
Appears in Collections:Research Papers (M.R.S. Rao)

Files in This Item:
File Description SizeFormat 
sl.no.121.2008 Cancer Biology & Therapy 7, 665-670 May.pdf
  Restricted Access
778.8 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.